Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.345 | A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therapy over 52 weeks in patients with type 2 diabetes mellitus and renal impairment and insufficient glycaemic control | Dr. Risa Ozaki |
| 2008.516 | A Phase III, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 1356 (5 mg), compared to placebo as add on to pre-existing antidiabetic therapy (insulin or any combination with insulin; sulphonylurea or glinides as monotherapy; pioglitazone or any other antidiabetics, excluding only DPP-4 inhibitors other than BI 1356) over 52 weeks in type 2 diabetic patients with severe chronic renal impairment | Dr. Ozaki Risa |
| 2013.282 | A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients with Benign Prostatic Hyperplasia (BPH) | Professor Ng Chi-Fai |
| 2004.091 | A Phase III, Randomized Open Label Multicenter Study Comparing GW572016 and Capecitabine (Xeloda) Versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer | Prof. Yeo Winnie |
| 2010.138 | A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With Metformin | Dr. Ozaki Risa |
| 2002.129 | A Phase III, Randomized, Double Blind, Multicenter, Multinational Study To Determine The Efficacy And Safety Of Tolterodine Prolonged Release Capsules in Children 5-10 y With Symptoms of Urge Urinary Incontinence, Suggestive of Detrusor Instability | Prof. Yeung Chung Kwong |
| 2018.433 | A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN HOSPITALIZED PATIENTS WITH SEVERE INFLUENZA |
Prof. HUI David Shu Cheong 許樹昌 |
| 2022.476 | A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2023.649 | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB COMPARED WITH PLACEBO PLUS ATEZOLIZUMAB IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIB, IIIA, OR SELECT IIIB, PD-L1 POSITIVE, NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED ADJUVANT PLATINUM-BASED CHEMOTHERAPY | Dr. LI Molly Siu Ching |
| 2017.267 | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2008.094 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer | Prof Winnie Yeo |
| 2023.345 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Prof. CHAN Stephen Lam 陳林 |
| 2015.506 | A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) – CHRONOS-3 |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2019.551 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2011.470 | A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared with Aclidinium Bromide, Formoterol Fumarate and Placebo for 24 Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD) | Professor Hui David Shu Cheong |
| 2020.457 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB IN COMBINATION WITH PACLITAXEL AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, UNRESECTABLE RECURRENT, OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 教授 |
| 2016.291 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2019.651 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) |
Dr. CHAN Stephen Lam 陳林 |
| 2023.567 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) | Prof. CHAN Stephen Lam |
| 2010.348 | A phase III, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therapy over 52 weeks in patients with type 2 diabetes mellitus and renal impairment and insufficient glycaemic control | Dr. Yu Wai Yin |
| 2023.518 | A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE |
Dr. CHONG Kam Lung 莊金隆 |
| 2017.423 | A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC) (POSEIDON) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2019.392 | A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine (HZ/su) when administered intramuscularly on a 0 and 2 month schedule to adults ≥ 50 years of age with a prior episode of Herpes Zoster. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2010.267 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older | Prof. HUI David Shu Cheong |
| 2010.266 | A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older | Prof. HUI David Shu Cheong |
| 2015.257 | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine |
Dr. LOONG Herbert 龍浩鋒 |
| 2021.151 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NOT PREVIOUSLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.152 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2024.230 | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Dr. LI Molly Siu Ching |
| 2011.437 | A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, when administered intramuscularly according to alternative 2-dose schedules in 9-14 year old healthy females | Prof. LEUNG Ting Fan |
| 2023.104 | A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA) | Prof. CHAN Stephen Lam |
| 2023.269 | A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in a wide patient population with HR+ HER2-early breast cancer (Adjuvant WIDER) | Prof. YEO Winnie |
| 2021.576 | A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS. AFLIBERCEPT TREAT AND EXTEND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (DIAGRID) |
Prof. LAI Timothy Yuk Yau 賴旭佑 教授 |
| 2016.096 | A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intramuscularly on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 and ZOSTER-022 studies. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2016.191 | A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2016.543 | A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) | Prof. TEOH Jeremy Yuen Chun |
| 2016.631 | A Phase IV multicenter, observational study in Chronic Immune Thrombocytopenia patients on eltrombopag treatment in emerging markets (CITE Study) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2013.255 | A Phase IV multicentre study of retigabine in refractory epilepsy patients in Hong Kong, SAR, China (The RR study) | Prof. LEUNG Howan |
| 2014.451 | A Phase IV Post-market, Observational, Retrospective & Prospective, Multi-centre Study of Lacosamide (Vimpat®) in Refractory, Partial-Onset Epilepsy patients in Hong Kong | Dr. LEUNG Howan |
| 2007.014 | A Phase IV, 2x2 Factorial, Double Blind Study of 24 Versus 48 Weeks and 90 Versus 180mcg Doses of Pegylated Interferon Alfa-2a 40KD (PEG-IFN, Ro 25-8310) in Adult Patients With HBeAg Positive Chronic Hepatitis B | Prof. Sung JY Joseph |
| 2004.065 | A Phase IV, Open-label, Multi-Centre, Community-based Trial Studying the Safety and Efficacy of Keppra As Adjunctive Therapy in Adult Subjects with Uncontrolled Partial Epilepsy | Dr. Kwan Patrick |
| 2009.260 | A phenomenology study of the lived experience of mothers caring for children hospitalized with injury or acute illness in general pediatric wards in Hong Kong | Ms LAU WAI KEE, VICKY |
| 2023.669 | A Physical Literacy-based intervention for Obese Teenagers (PLOT Trial): A randomized controlled trial | Dr. CHAN Crystal Ying |
| 2022.006 | A physiological-based model to predict treatment outcomes in children with obstructive sleep apnoea |
Prof. LI Albert Martin Man Chim 李民瞻 |
| 2014.291 | A pilot “SCIATICA” study - Stem Cell Intra-Articular Therapeutic Injection for Carpal Affections | Dr. TSE Wing Lim |
| 2008.402 | A Pilot and Feasibility Study to Evaluate Capsule Endoscopy in Subjects Presenting with Acute, Overt Upper Gastrointestinal Hemorrhage | Prof. Sung Joseph |
| 2012.192 | A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy in patients with metastatic colorectal cancer who were previously treated with cetuximab-based chemotherapy | Prof. MA Brigette |
| 2013.379 | A pilot cross-sectional study examining the dietary intakes, nutrient intakes and nutritional status of Chinese women from early pregnancy to early postpartum in Hong Kong | Prof Chan Suk-mei, Ruth |
| 2016.515 | A pilot dose-finding study of high-intensity focused ultrasound (HIFU) in inducing ovulation in women with polycystic ovarian syndrome | Prof. CHUNG Jacqueline Pui Wah |
| 2019.615 | A pilot fall prevention programme using STRATIFY at triage of Emergency Department in Hong Kong |
Mr. LAU Wai Yuen 劉偉源 |
Page 24 of 253.